TARRYTOWN, N.Y., April 29, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced the presentation of positive long-term results and subgroup analyses from the pivotal ...

TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD ® (aflibercept) ...

Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD). The findings, ...

Alvotech and Teva Pharmaceuticals announced that the FDA has accepted the Biologics License Application for AVT06, a proposed biosimilar to Eylea® (aflibercept), used in treating serious eye disorders ...

The story around Regeneron is shifting, and one big player just made it official.

If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are indicated ...

European Commission grants marketing approval for Eylea 8 mg to treat macular edema following RVO, including branch, central and hemiretinal vein occlusion: Berlin Monday, January ...

The U.S. Food and Drug Administration has accepted for Priority Review Regeneron Pharmaceuticals, Inc.’s (NASDAQ:REGN) supplemental Biologics License Application (sBLA) for Eylea HD (aflibercept) ...